St Vincent Healthcare
- Type
- Teaching hospital
- Where
- Billings, MT
- Medicare CCN
- 270049
- Received
- $1,121,815 in 274 records, 2020 ($4,369 general, $1,117,446 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: ST. VINCENT HEALTHCARE Fuzzy (name and state)
- Trademark owner: St. Vincent Healthcare Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 8 | $4,369 |
| 2020 | Research payment | 266 | $1,117,446 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 194 | $685,926 | 2020 |
| SEAGEN INC. | 15 | $149,704 | 2020 |
| EMD Serono, Inc. | 36 | $86,562 | 2020 |
| Novartis Pharmaceuticals Corporation | 3 | $65,600 | 2020 |
| Acerta Pharma LLC | 1 | $61,774 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 4 | $26,573 | 2020 |
| ABBVIE INC. | 1 | $20,075 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $6,039 | 2020 |
| Amgen Inc. | 1 | $4,565 | 2020 |
| United Therapeutics Corporation | 2 | $3,807 | 2020 |
| PFIZER INC. | 2 | $3,656 | 2020 |
| Celgene Corporation | 1 | $2,200 | 2020 |
| Abbott Laboratories | 1 | $1,950 | 2020 |
| Pharmacyclics LLC, an AbbVie Company | 4 | $960 | 2020 |
| Medtronic MiniMed, Inc. | 1 | $600 | 2020 |
| KCI USA, Inc. | 1 | $500 | 2020 |
| Boston Scientific Corporation | 1 | $325 | 2020 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $325 | 2020 |
| AstraZeneca Pharmaceuticals LP | 1 | $325 | 2020 |
| Chiesi USA, Inc. | 1 | $325 | 2020 |
| GE HEALTHCARE | 1 | $19 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 266 | $1,117,446 |
| Consulting Fee | 1 | $1,950 |
| Space rental or facility fees (teaching hospital only) | 2 | $650 |
| Grant | 2 | $650 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $600 |
| Education | 2 | $519 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-28 | SEAGEN INC. | $7,708 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-28 | SEAGEN INC. | $7,708 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-28 | SEAGEN INC. | $7,666 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-22 | SEAGEN INC. | $10,356 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-22 | SEAGEN INC. | $8,605 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-22 | SEAGEN INC. | $7,987 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-22 | SEAGEN INC. | $7,987 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-12-21 | Medtronic MiniMed, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-12-17 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-12-17 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $210 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-12-15 | EMD Serono, Inc. | $8,953 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-12-07 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Che | 2020 |
| 2020-12-03 | SEAGEN INC. | $7,666 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-11-24 | SEAGEN INC. | $3,315 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-11-23 | Merck Sharp & Dohme LLC | $37 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2020 |
| 2020-11-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-11-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-11-12 | SEAGEN INC. | $7,666 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-11-11 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $91 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $68 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $48 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $41 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $41 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-10-27 | Merck Sharp & Dohme LLC | $62 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-10-27 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-10-23 | SEAGEN INC. | $11,869 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-10-20 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-10-20 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-10-20 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-10-20 | Merck Sharp & Dohme LLC | $226 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2020 |
| 2020-10-15 | SEAGEN INC. | $19,166 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-10-15 | SEAGEN INC. | $3,833 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-10-15 | Abbott Laboratories | $1,950 | Consulting Fee | Cash or cash equivalent | Neuromodulation Dspsbls and Accs Device, Cardiac Arrhythmias and Heart Failure | 2020 | |
| 2020-10-15 | Merck Sharp & Dohme LLC | $148 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2020 |
| 2020-10-14 | Merck Sharp & Dohme LLC | $600 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2020 |
| 2020-10-13 | EMD Serono, Inc. | $4,309 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-10-09 | Merck Sharp & Dohme LLC | $8,227 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-10-09 | Merck Sharp & Dohme LLC | $8,227 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-10-07 | Merck Sharp & Dohme LLC | $20,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-10-05 | SEAGEN INC. | $15,416 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $1,181 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $180 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-09-22 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-09-22 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-09-22 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-09-11 | Merck Sharp & Dohme LLC | $253 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-09-03 | Merck Sharp & Dohme LLC | $585 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-09-01 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-08-31 | Bayer Healthcare Pharmaceuticals Inc. | $4,478 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2020 |
| 2020-08-28 | Merck Sharp & Dohme LLC | $367 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-28 | GE HEALTHCARE | $19 | Education | Cash or cash equivalent | 2020 | ||
| 2020-08-26 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-19 | PFIZER INC. | $3,200 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $247 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $47 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-08-07 | Merck Sharp & Dohme LLC | $3,600 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-08-04 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-08-04 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-08-04 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-07-29 | United Therapeutics Corporation | $2,710 | Research payment | Cash or cash equivalent | UNITUXIN Drug, Oncology | A TWO-PART OPEN-LABEL RANDOMIZED PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREA | 2020 |
| 2020-07-28 | Merck Sharp & Dohme LLC | $326 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-07-28 | Merck Sharp & Dohme LLC | $237 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-07-27 | SEAGEN INC. | $22,750 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-07-27 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $1,426 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-07-17 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2020 |
| 2020-07-15 | Merck Sharp & Dohme LLC | $8,227 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-07-09 | EMD Serono, Inc. | $8,953 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $200 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $193 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $94 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $66 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $47 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $27 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $18 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $14 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-07-03 | Merck Sharp & Dohme LLC | $7,055 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2020 |
| 2020-07-02 | E.R. Squibb & Sons, L.L.C. | $12,428 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemother | 2020 |
| 2020-06-26 | Merck Sharp & Dohme LLC | $4,545 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-06-25 | Merck Sharp & Dohme LLC | $148 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-06-25 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-06-24 | Merck Sharp & Dohme LLC | $2,446 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-06-24 | Merck Sharp & Dohme LLC | $1,800 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-12 | United Therapeutics Corporation | $1,097 | Research payment | Cash or cash equivalent | UNITUXIN Drug, Oncology | A TWO-PART OPEN-LABEL RANDOMIZED PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREA | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $3,066 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-06-08 | Bayer Healthcare Pharmaceuticals Inc. | $1,560 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $1,355 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $58 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $55 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-06-05 | Merck Sharp & Dohme LLC | $10,198 | Research payment | Cash or cash equivalent | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-05-26 | Merck Sharp & Dohme LLC | $2,587 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-05-26 | Merck Sharp & Dohme LLC | $53 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-05-21 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-05-21 | Merck Sharp & Dohme LLC | $1,426 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-05-13 | Merck Sharp & Dohme LLC | $187 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-05-08 | Merck Sharp & Dohme LLC | $8,227 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-05-08 | Merck Sharp & Dohme LLC | $3,552 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-05-07 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-04-30 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-04-30 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2020 |
| 2020-04-30 | Novartis Pharmaceuticals Corporation | $1,535 | Research payment | Cash or cash equivalent | TYKERB Drug, ONCOLOGY | A RANDOMIZED PHASE III OPEN LABEL STUDY OF LAPATINIB PLUS TRASTUZUMAB VERSUS TRASTUZUMAB AS CONTINUED HER2 SUPPRESSION T | 2020 |
| 2020-04-27 | Merck Sharp & Dohme LLC | $46,250 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-04-27 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2020 |
| 2020-04-21 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-04-21 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-04-21 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-04-20 | Novartis Pharmaceuticals Corporation | $37,938 | Research payment | In-kind items and services | KISQALI Drug, ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | 2020 |
| 2020-04-17 | Merck Sharp & Dohme LLC | $8,847 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-17 | Merck Sharp & Dohme LLC | $485 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-15 | Merck Sharp & Dohme LLC | $7,936 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-14 | EMD Serono, Inc. | $8,953 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $14,086 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $8,847 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $8,847 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $8,847 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $6,745 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $6,520 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $1,199 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-10 | Merck Sharp & Dohme LLC | $1,169 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $2,431 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $187 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $33 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-03-31 | Merck Sharp & Dohme LLC | $117 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-03-26 | Merck Sharp & Dohme LLC | $63 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2020 |
| 2020-03-20 | Merck Sharp & Dohme LLC | $1,800 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2020 |
| 2020-03-17 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-03-17 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-03-17 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-03-17 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | PD-L 1 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2020 |
| 2020-03-16 | Merck Sharp & Dohme LLC | $46,246 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-03-10 | ABBVIE INC. | $20,075 | Research payment | Cash or cash equivalent | M14-239 | 2020 | |
| 2020-03-09 | Merck Sharp & Dohme LLC | $231 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $212 | Research payment | In-kind items and services | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
The latest 200 records of 274.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Billings, MT, county Yellowstone County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Billings, MT | County Yellowstone County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 119,434 | 168,957 | 1,116,875 |
| Population, 2020 census P1 | 117,116 | 164,731 | 1,084,225 |
| Median age B01002 | 38.8 | 39.0 | 40.4 |
| Under 18 B01001 | 22.0% | 23.0% | 21.0% |
| 65 and over B01001 | 18.8% | 18.3% | 20.1% |
| Households B11001 | 50,994 | 69,897 | 458,859 |
| Foreign born B05002 | 2.1% | 1.9% | 2.3% |
| Median household income B19013 | $73,712 | $76,570 | $72,509 |
| Median family income B19113 | $99,619 | $99,949 | $92,794 |
| Per capita income B19301 | $43,934 | $43,898 | $41,711 |
| Poverty rate B17001 | 9.8% | 9.2% | 11.5% |
| Unemployment rate B23025 | 3.5% | 3.4% | 3.6% |
| Civilian labor force B23025 | 63,477 | 88,987 | 568,568 |
| Mean commute (minutes) B08013 | 16.5 | 18.6 | 19.1 |
| Bachelor's degree or higher B15003 | 36.9% | 34.1% | 35.2% |
| Housing units B25001 | 54,346 | 74,239 | 528,419 |
| Owner-occupied B25003 | 64.8% | 69.6% | 69.2% |
| Renters B25003 | 35.2% | 30.4% | 30.8% |
| Median home value B25077 | $343,400 | $349,500 | $375,800 |
| Median gross rent B25064 | $1,138 | $1,131 | $1,081 |
| White, not Hispanic B03002 | 82.5% | 83.4% | 83.6% |
| Black B03002 | 0.4% | 0.4% | 0.4% |
| Hispanic or Latino B03002 | 7.4% | 6.6% | 4.6% |
| Asian B03002 | 0.8% | 0.7% | 0.8% |
| American Indian and Alaska Native B03002 | 3.9% | 3.6% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Billings, MT.
Comments